now recent development Steve. update Thank programs. in and brief right. on research give you, our progress a All I’ll
start Ia/Ib NASH Let’s slide, potential program. a treatment CBXXXX is Next testing clinical for Phase please? in as with clinical currently obesity. the and
reminder, and, day the been a not liver be and in will double-blind, on half that short effects and of the screening. a placebo-controlled number designed Phase pivotal fat, stage is enrolling and reached This one data. once looking a for at minimum and currently, various level the dose study XX target MRI-PDFF, liver with be have CBXXXX This NASH, obesity is have by significant one and enrollment quarter which of us. evaluation of to while slower availability unpredictable a have fat XX% already of As biomarkers subjects to study, of fat subjects progress baseline currently NAFLD. Many top not subjects to the weight assess so that assessed more Changes in the the trends in this COVID-XX-related experiencing our of subjects due recently, of due of And their subjects phase enrolled study the dosing end at given rate, are their results II pandemic Ib issues as of obese disease. the current body Phase liver dose site initial positive second These progress we’ve a metabolic relevant will potential on with CBXXXX are which we over during subjects the the a change actively all of enrolling must is study, in to the such similar to to expect this are tests types made have of new of if appropriate other the may companies to other the of to clinical XXXX, ongoing sites. studies. COVID-XX factors included line holidays. issues, precautions, With pause, COVID-XX-related continues We COVID-XX issues subjects. continues at the site nature unique despite and safety We’ve dropouts already treatment.
expect completed follow-up. We subject has update once study of status the their last the to the
completed discussed trial as this process, So study this the enrollment for the last a slide, on Next please? This subject be as and a in continues continuous has starting able call, process involves they’re for enrolled, enter last the as has safety. subject up the the individual to follow-up. study. simplified shown clinical as soon each is we diagram. process Each until final dosed to followed rolling for study This subject
be that So initial of the continuous. show tested for the the must to the process period enroll. list They receives enrolled qualify study participation, to and is the study also and to of dose, a and there still subjects for they then through or of carefully for the have recruiting they they no dosed our observation We they consent fat. meeting waiting that tests liver all to scan ensure subject identified are the at extensive including entered are potential sufficient database sites to last or subjects screened without advertising. ensure rest criteria qualifies subject can then by a When study, screening for there’s each and the from When the safety for the be issues. their passes clinical follow-up MRI into
entered the At at data this with not a effectively the staggered times, the we collected blinded, entire subjects way liver stage, to and have the this various into data the do collected, finally subjects are yet systematically process who of body final the follow-up. and and database. are are different all follow-up levels errors, And meaning study create who pharmacokinetics, placebo. data are the When So the is analysis a in received a enter begins. know throughout and weight after the Data or are process all the fat, checked steps required data rolling pipeline in errors process database subjects for then and then through manner we all unblinded moving completed and received CBXXXX locked. for all have data the resolved then the all final the safety, biomarker been and
and target now we last the when have update stated, completed will half of final last follow-up. we So as their dosing, subject the subjects completes the
please? to significant programs. programs made starting multiple slide, that is have strong we’ve in in novel a where analogs. fibrosis Now focus of I’ll progress today family peptides anti-inflammatory CBXXXX moving Next and peptides idiopathic the and IPF. encoded vivo preclinical vitro a in models properties X to our quarter, pulmonary last or antifibrotic related our of mitochondrially antifibrotic molecules on during with or This
these on of lung the fibrotic process key and transformation based production to cells, by studies conducted fibrosis cells. involved fibrotic reducing Now of pathological in human from by proteins the work in healthy cells cultured peptides inhibiting cell
have in discoveries Then therapeutic of outcomes, animals In immediate of therapeutic week IPF. IPF reducing bleomycin of lungs the model, induction and XX collagen, extent by levels in cytokine clear showed the of on in inflammation peptides animals all analogs We animal secretion of positive model. in multiple showed treatment the fibrosis, X that the same efficacy effects used fibrosis antifibrotic initial built of in effects lung after treatment days the the we further study the is inflammation. first reducing beginning fibrosis, later. We we to with those had and model on of CBXXXX demonstrated the demonstrating induce bleomycin without the and which prophylactic anti-inflammatory fibrosis reduce models
in top produced care, necessary expect Now that a complete of subject in a approved activities the most analog IND-enabling have of the IPF. standard the those to NASH. the a an candidate use combination that the successful remaining the drugs model, of potential broad their diseases, we’re XXXX, dosing early such X At therapy to the outcome time, end identification recently, effects support of potentially CBXXXX a with as CBXXXX fibrosis This the of antifibrotic fibrotic of greater for same for one use IPF around there’s We IND of effects nintedanib, than CBXXXX kidney and we initiate models, required using anti-inflammatory this in other and shown activities current to with alone. the first of of filing nintedanib potential quarter and in current of exploring goal then treating therapeutic points to on to XXXX. potential analogs with of and clinical analogs activities currently scleroderma, suggests preclinical and
Next slide, see please? American of that Meeting. data were Thoracic summer at So on some we Annual slide, Society this the Virtual released the this
potential here Looking therapeutic monotherapy the at model IPF. for mouse using of
the MBTX, treatment In previously with the addition analogs alone then in called red to in treated were on placebo first green the and animals CBXXXX compared to bars. vehicle analog newer X bars, nintedanib
approved X Now drugs. and including is inhibitor has progression of several significant the off-target nausea, of slowing nintedanib IPF But targets, to diarrhea. effects, leading a IPF. also different nintedanib It’s kinase one vomiting that a tyrosine the blocks of
you tissue effects anti-inflammatory and the the across both in fluid, fluid. lung reductions the fibrosis, of in lymphocytes weight, in and terms antifibrotic levels secreted lung including board, into the Here, reduced lung consistent of we in reduced see have collagen, inflammation lung reduced
this moving at analog combination case, with the the a look most So our to care, nintedanib. the now study ago. please? designed of to potential was released for recent standard in data just of X CBXXXX slide, weeks This Next
alone treatments you together. again therapeutic alone, blue the with of fibrosis. after dark treatment X The was alone. nintedanib mouse was to The combination for can nintedanib of in the the both the of conducted bars model IPF, combination CBXXXX-X bleomycin days induction see of bars and And green nintedanib study Our are CBXXXX-X the the compared included here, initiated treatments. effects drugs of these where
to -- the slides. study also reduction can other endpoints fibrosis, You for other positive lung slides the the that next on greater see combination. effect a in and weight there was lung carried of levels combination And over collagen
Okay. please? Next slide,
as the key as the same the pro-inflammatory fluid. inflammatory lung involved in than macrophage in with cytokines such as nintedanib alone. the levels as the see protein, nintedanib other CBXXXX the of So chemoattractant these we This much chemokines IL-X-beta, well the includes TNF-alpha pro-inflammatory of at was response, all inflammatory cytokines MCP-X analog cases, MIP-X-alpha. more key here cytokines monocyte and the into and effective such IL-X experiment, reducing secreted combination protein, In
So Next at this fluid. looking slide cells data the of slide, last on we’re the into please? inflammatory here, long infiltration
analog You dark with again in treatment lymphocytes can when compared macrophages, see the effective with reducing nintedanib of green the blue nintedanib bar and that the with neutrophils combination bars. more of was at CBXXXX the in infiltration alone the
the Toby Interstitial Now of also fibrosis Next School please? National Clinical Maher. of this University is Professor program slide, the College on Lung the of is at Southern Imperial the Professor the He Heart of of at Disease Dr. Medicine our adviser Lung key and Medicine California Keck and London. at Institute of
believes key Now been Phase lung a Phase has and of Maher in IPF that XX the care, IPF that recent for In from to need impact leader compelling fibrotic are IPF he of new the of opinion mechanisms treatments. CohBar’s likely combinations and future involved CBXXXX Dr. more treatment for Dr. Dr. on current nintedanib our clinical the combination including gave devastating a with data perspective diseases analogs Maher will towards than preclinical step Ib new call, of unmet standard continuing towards with IV, goal. move in studies. Maher, According trials to in
damage. CBXXXX mortality now the by a our in of potential to syndrome, COVID-XX-related in many simultaneously that ARDS This Moving distress have analogs. acute that of please? respiratory ARDS, slide, peptide blocking the family and is lead to different reduce analogs or processes Next global to
failure. see a thrombosis disease. you that In multi-organ cytokine can than accumulation, can cause is it right, to storm more even sepsis, severe and lead inflammation fluid a the lung can that and leakage, cases, on COVID-XX Now vascular
no failure, And affects million cardiac ARDS So treat failure. approved together, respiratory people. even these lead damaging without drugs even ARDS. COVID-XX, effects the stroke of X multi-organ failure, are to and There virus to can
by that tone, selectively of adipokine fluid work of numerous apelin has key analogs protective animals been stroke. broad to ARDS, cytokine activating in pathway including Apelin the inflammation control receptor, CBXXXX systems, thrombosis has clotting, and shown signaling signaling rebalancing effects blood production. sepsis, a on the and models protect Our levels, vascular
of engaging damaging COVID-XX. So many the of receptor block effects apelin these the has potential to
confirmatory shared We accumulation efficacy showing reduced vivo in CBXXXX leading now cytokines. decreased model data of we’re in of and forward moving Steve. towards to pro-inflammatory I’ll of currently conducting lungs, initiation in the animal the candidate potential return the ARDS of our have studies IND-enabling previously model call analogs in selection, the with scale and that, fluid an secretion up And studies. to ARDS, And
